2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Pathway-level mutation analysis in primary high-grade serous ovarian cancer and matched brain metastases

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Brain metastases (BMs) in ovarian cancer (OC) are a rare event. BMs occur most frequently in high-grade serous (HGS) OC. The molecular features of BMs in HGSOC are poorly understood. We performed a whole-exome sequencing analysis of ten matched pairs of formalin-fixed paraffin-embedded samples from primary HGSOC and corresponding BMs. Enrichment significance ( p value; false discovery rate) was computed using the Reactome, the Kyoto Encyclopedia of Genes and Genomes pathway collections, and the Gene Ontology Biological Processes. Germline DNA damage repair variants were found in seven cases (70%) and involved the BRCA1, BRCA2, ATM, RAD50, ERCC4, RPA1, MLHI, and ATR genes. Somatic mutations of TP53 were found in nine cases (90%) and were the only stable mutations between the primary tumor and BMs. Disturbed pathways in BMs versus primary HGSOC constituted a complex network and included the cell cycle, the degradation of the extracellular matrix, cell junction organization, nucleotide metabolism, lipid metabolism, the immune system, G-protein-coupled receptors, intracellular vesicular transport, and reaction to chemical stimuli (Golgi vesicle transport and olfactory signaling). Pathway analysis approaches allow for a more intuitive interpretation of the data as compared to considering single-gene aberrations and provide an opportunity to identify clinically informative alterations in HGSOC BM.

          Related collections

          Most cited references53

          • Record: found
          • Abstract: found
          • Article: not found

          Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

          This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer. Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Overall incidence was from 2-fold to 3-fold higher in transitioned versus transitioning countries for both sexes, whereas mortality varied <2-fold for men and little for women. Death rates for female breast and cervical cancers, however, were considerably higher in transitioning versus transitioned countries (15.0 vs 12.8 per 100,000 and 12.4 vs 5.2 per 100,000, respectively). The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020, with a larger increase in transitioning (64% to 95%) versus transitioned (32% to 56%) countries due to demographic changes, although this may be further exacerbated by increasing risk factors associated with globalization and a growing economy. Efforts to build a sustainable infrastructure for the dissemination of cancer prevention measures and provision of cancer care in transitioning countries is critical for global cancer control.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            KEGG: kyoto encyclopedia of genes and genomes.

            M Kanehisa (2000)
            KEGG (Kyoto Encyclopedia of Genes and Genomes) is a knowledge base for systematic analysis of gene functions, linking genomic information with higher order functional information. The genomic information is stored in the GENES database, which is a collection of gene catalogs for all the completely sequenced genomes and some partial genomes with up-to-date annotation of gene functions. The higher order functional information is stored in the PATHWAY database, which contains graphical representations of cellular processes, such as metabolism, membrane transport, signal transduction and cell cycle. The PATHWAY database is supplemented by a set of ortholog group tables for the information about conserved subpathways (pathway motifs), which are often encoded by positionally coupled genes on the chromosome and which are especially useful in predicting gene functions. A third database in KEGG is LIGAND for the information about chemical compounds, enzyme molecules and enzymatic reactions. KEGG provides Java graphics tools for browsing genome maps, comparing two genome maps and manipulating expression maps, as well as computational tools for sequence comparison, graph comparison and path computation. The KEGG databases are daily updated and made freely available (http://www. genome.ad.jp/kegg/).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found
              Is Open Access

              Comprehensive molecular portraits of human breast tumors

              Summary We analyzed primary breast cancers by genomic DNA copy number arrays, DNA methylation, exome sequencing, mRNA arrays, microRNA sequencing and reverse phase protein arrays. Our ability to integrate information across platforms provided key insights into previously-defined gene expression subtypes and demonstrated the existence of four main breast cancer classes when combining data from five platforms, each of which shows significant molecular heterogeneity. Somatic mutations in only three genes (TP53, PIK3CA and GATA3) occurred at > 10% incidence across all breast cancers; however, there were numerous subtype-associated and novel gene mutations including the enrichment of specific mutations in GATA3, PIK3CA and MAP3K1 with the Luminal A subtype. We identified two novel protein expression-defined subgroups, possibly contributed by stromal/microenvironmental elements, and integrated analyses identified specific signaling pathways dominant in each molecular subtype including a HER2/p-HER2/HER1/p-HER1 signature within the HER2-Enriched expression subtype. Comparison of Basal-like breast tumors with high-grade Serous Ovarian tumors showed many molecular commonalities, suggesting a related etiology and similar therapeutic opportunities. The biologic finding of the four main breast cancer subtypes caused by different subsets of genetic and epigenetic abnormalities raises the hypothesis that much of the clinically observable plasticity and heterogeneity occurs within, and not across, these major biologic subtypes of breast cancer.
                Bookmark

                Author and article information

                Contributors
                rdtt@wp.pl , rduchnowska@wim.mil.pl
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                29 November 2022
                29 November 2022
                2022
                : 12
                : 20537
                Affiliations
                [1 ]GRID grid.415641.3, ISNI 0000 0004 0620 0839, Oncology Department, , Military Institute of Medicine - National Research Institute, ; Szaserów St. 128, 04-141 Warsaw, Poland
                [2 ]GRID grid.11451.30, ISNI 0000 0001 0531 3426, Laboratory of Translational Oncology, Intercollegiate Faculty of Biotechnology, , University of Gdańsk and Medical University of Gdańsk, ; Gdańsk, Poland
                [3 ]GRID grid.11451.30, ISNI 0000 0001 0531 3426, Department of Pathology, , Medical University of Gdańsk, ; Gdańsk, Poland
                [4 ]GRID grid.7914.b, ISNI 0000 0004 1936 7443, Department of Clinical Science, , University of Bergen, ; Bergen, Norway
                [5 ]Data4Cure, Inc., La Jolla, CA USA
                [6 ]Oncology Department Oncology Center, Gdynia, Poland
                [7 ]GRID grid.11451.30, ISNI 0000 0001 0531 3426, Department of Pathology and Neuropathology, , Medical University of Gdańsk, ; Gdańsk, Poland
                [8 ]GRID grid.11451.30, ISNI 0000 0001 0531 3426, Department of Oncology and Radiotherapy, , Medical University of Gdańsk, ; Gdańsk, Poland
                [9 ]Neurosurgery Department, Regional Specialist Hospital, Olsztyn, Poland
                [10 ]GRID grid.412607.6, ISNI 0000 0001 2149 6795, Department of Oncology, Collegium Medicum, , University of Warmia and Mazury, ; Olsztyn, Poland
                [11 ]GRID grid.418165.f, ISNI 0000 0004 0540 2543, Department of Pathology, , Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, ; Warsaw, Poland
                [12 ]GRID grid.418165.f, ISNI 0000 0004 0540 2543, Department of Neurosurgery, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, ; Warsaw, Poland
                [13 ]GRID grid.411484.c, ISNI 0000 0001 1033 7158, Department of Neurosurgery and Paediatric Neurosurgery, , Medical University of Lublin, ; Lublin, Poland
                Article
                23788
                10.1038/s41598-022-23788-4
                9708673
                36446793
                936596c7-95b0-4e80-9c3f-0c7148966661
                © The Author(s) 2022

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 27 April 2022
                : 4 November 2022
                Funding
                Funded by: The National Science Centre, Poland
                Award ID: Grant 2018/02/X/NZ5/01408.
                Award Recipient :
                Funded by: Medical University of Gdańsk, Poland
                Award ID: Statutory grant ST-23, 02-0023/07
                Award Recipient :
                Categories
                Article
                Custom metadata
                © The Author(s) 2022

                Uncategorized
                cancer,molecular biology,neuroscience,diseases,medical research,molecular medicine,oncology,pathogenesis

                Comments

                Comment on this article